Pfizer
Trade Pfizer 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About PFE
Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.
PFE Key Statistics
Stock Snapshot
The current Pfizer(PFE) stock price is $26.38, with a market capitalization of 149.72B. The stock trades at a price-to-earnings (P/E) ratio of 19.42 and offers a dividend yield of 6.5%.
On 2026-05-04, Pfizer(PFE) stock traded between a low of $26.15 and a high of $26.51. Shares are currently priced at $26.38, which is +0.9% above the low and -0.5% below the high.
The Pfizer(PFE)'s current trading volume is 34.58M, compared to an average daily volume of 36.25M.
In the last year, Pfizer(PFE) shares hit a 52-week high of $28.75 and a 52-week low of $21.97.
In the last year, Pfizer(PFE) shares hit a 52-week high of $28.75 and a 52-week low of $21.97.
PFE News
The approval covers estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-), estrogen receptor 1 (ESR1)-mutated advanced or m...
Benzinga Pro puts the consensus estimate for Pfizer's quarterly revenue at $13.8 billion. Pfizer reported $13.71 billion last year. With the recent buzz around...
Pharmaceuticals giant Pfizer (PFE) is set to report its Q1 earnings on May 5. The stock is up over 7% in the year-to-date as investors get excited about its dru...
Analyst ratings
50%
of 30 ratingsMore PFE News
Key Points Pfizer is facing headwinds today, which is why investors seem to be ignoring the stock. The giant pharmaceutical company is still an industry leade...
In late April 2026, Pfizer resolved US patent disputes over its cardiomyopathy drug VYNDAMAX by settling with three generic manufacturers, effectively extending...
Pfizer (NYSE:PFE) reported positive Phase 3 results for ELREXFIO (elranatamab) in the MagnetisMM-5 study in adults with relapsed or refractory multiple myeloma....
Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of mark...
The U.S. Food and Drug Administration on Friday approved vepdegestrant, a breast cancer therapy developed by Pfizer (PFE) and Arvinas (ARVN) under the brand nam...
Key Points High-yield stocks may offer impressive levels of passive income -- but it’s important to understand why the particular stock is high-yield. Dividen...
Pfizer Inc. (NYSE:PFE) on Wednesday shared topline results from the late-stage study of its cancer treatment, ELREXFIO (elranatamab). Multiple myeloma is an agg...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.